skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
GVAX Lung Cancer Vaccine (Code C1979)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: GVAX Lung Cancer Vaccine

Definition: An autologous lung cancer vaccine consisting of patient-specific lung cancer cells genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), an immunostimulatory cytokine. GM-CSF modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function and may augment host antitumoral immunity. For safety, cells are irradiated prior to vaccination. (NCI04)

Label: GVAX Lung Cancer Vaccine

NCI Thesaurus Code: C1979 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1328108  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
GVAX Autologous Lung Cancer Vaccine
GVAX Lung Cancer Vaccine

External Source Codes: 
NSC Code 730428 (see NCI DTP info)
PDQ Closed Trial Search ID 346435
PDQ Open Trial Search ID 346435 (check for NCI PDQ open clinical trial info)
UMLS CUI C1328108

Other Properties:
     Name Value (qualifiers indented underneath)
code C1979
Legacy_Concept_Name GVAX_Lung_Cancer_Vaccine
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom